SLDB
Solid BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The best case is that SGT-003 keeps showing differentiated tolerability and biomarker/functional support, Phase 3 dosing starts on time, and FDA discussions make an accelerated route look viable; combined with runway into H1 2028, that can support a sharper rerating from a depressed base.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -7.1.
What can break
Competitive pressure from Sarepta, REGENXBIO, and other Duchenne programs could compress SLDB’s differentiation narrative.
Momentum
30
Value
41
Sentiment
79
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.60 · Bull $11.50 · Bear $5.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $15.75
Why
Momentum30 · Δ7d +6.9
Value41 · Δ7d +0.1
Sentiment79 · Δ7d -7.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
30
34% active weight
Current posture
7d trendImproving
Δ7d
+6.9
Δ21d
-25.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
79
33% active weight
Current posture
7d trendSoftening
Δ7d
-7.1
Δ21d
+16.3
Why this grade
Composite grade C. Momentum 29.8 / Value 41.1 / Sentiment 79.3
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$647.8M
Beta
2.68
Shares Out
77.91M
P/E (TTM) · Derived
-2.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.65
Rev YoY
-
EPS YoY
+38.6%
Gross Margin
-
Op Margin
-
Net Debt
-$147.69M
Current Ratio
6.74
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology